Jasper Therapeutics, Inc. (JSPR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics targeting mast cell-driven diseases, primarily chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company's lead product candidate is briquilimab. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(26,723) | $(14,583) | $(47,964) | $(28,311) |
| Operating Expenses | $27,076 | $15,993 | $48,878 | $31,065 |
| Cash & Equivalents (End of Period) | $39,510 | $71,637 | $39,510 | $71,637 |
| Operating Cash Flow (YTD) | $(38,295) | $(27,416) | $(38,295) | $(27,416) |
| Accumulated Deficit | $(288,833) | $(197,911) | $(288,833) | $(197,911) |
Note: The company has no revenue and is pre-commercial. Margins are not applicable.
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the six months ended June 30, 2025, increased by 69% to $48.0 million compared to $28.3 million in the prior year period. Operating expenses rose 57% to $48.9 million.
- R&D Escalation: Research and development expenses increased by 73% year-over-year (YTD), driven by higher costs for the CSU program, the initiation of the asthma program, and increased Contract Manufacturing Organization (CMO) expenses.
- Cash Position: Cash and cash equivalents decreased by approximately $32.1 million during the first half of 2025, leaving $39.5 million as of June 30, 2025.
- Financing Activity: The company raised approximately $5.9 million through an At-The-Market (ATM) offering in Q2 2025. This contrasts with Q2 2024, which saw no significant equity raises (the major underwritten offering occurred in Q1 2024).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash is insufficient to fund operations without additional financing.
- Corporate Reorganization (Subsequent Event): On July 8, 2025, the company implemented a workforce reduction of approximately 50% to extend its cash runway. Estimated costs are $1.9 million, primarily severance, to be recognized in Q3 2025.
- Strategic Pivot: Following the reorganization, the company halted enrollment in its Phase 1b/2a asthma study (ETESIAN) and discontinued other clinical/preclinical programs (including SCID) to focus exclusively on briquilimab for chronic urticaria.
- Clinical Investigation: The company is investigating a specific drug product lot used in the BEACON (CSU) and ETESIAN (Asthma) studies due to an atypical absence of efficacy in specific cohorts. New drug supply from a different lot has been provided.
- Capital Needs: The company expects to require substantial additional funding through equity or debt financings to continue development. It has an effective S-3 shelf registration with approximately $294.1 million available.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $39.5 million cash balance against the revised operating plan post-workforce reduction.
- Drug Lot Investigation: Monitor the outcome of the investigation into the specific drug product lot causing atypical efficacy results in the BEACON study.
- Financing Terms: Assess the terms and dilution impact of any future equity raises required to fund operations beyond the current cash position.
- Reorganization Costs: Confirm the actual recognition of the estimated $1.9 million severance costs in the Q3 2025 filing.
- Program Focus: Validate the strategic decision to halt the asthma and SCID programs and the impact on the overall pipeline valuation.